

Francesco Morra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9237393/publications.pdf>

Version: 2024-02-01

14
papers

442
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

861
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress. <i>Cancers</i> , 2021, 13, 3822.	3.7	3
2	The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis. <i>Heliyon</i> , 2021, 7, e08399.	3.2	3
3	NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatin Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. <i>Cancers</i> , 2020, 12, 44.	3.7	4
4	Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2019, 135, 56-65.	2.0	14
5	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3100.	4.1	32
6	CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC. <i>Cancers</i> , 2019, 11, 1582.	3.7	11
7	CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 90.	8.6	29
8	CCDC6: the identity of a protein known to be partner in fusion. <i>International Journal of Cancer</i> , 2018, 142, 1300-1308.	5.1	26
9	USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. <i>Lung Cancer</i> , 2017, 107, 41-49.	2.0	51
10	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1374.	4.1	47
11	The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 31815-31829.	1.8	51
12	Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 179.	8.6	88
13	FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC. <i>Oncotarget</i> , 2015, 6, 12697-12709.	1.8	42
14	New therapeutic perspectives in <sc>CCDC</sc>6 deficient lung cancer cells. <i>International Journal of Cancer</i> , 2015, 136, 2146-2157.	5.1	41